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Abstract
Background: Albumin is a key regulator of fluid distribution within the extracellular space and has several
properties beyond its oncotic activity. The accumulating evidence suggests that supplementation of albumin may
provide survival advantages only when the insult is severe as in patients with septic shock.
Methods/design: The randomized controlled multicentre study of albumin replacement therapy in septic shock
(ARISS) investigates whether the replacement with albumin and the maintenance of its serum levels of at least 30
g/l for 28 days improve survival in patients with septic shock compared to resuscitation and volume maintenance
without albumin. Adult patients (≥ 18 years) with septic shock are randomly assigned within a maximum of 24 h
after the onset of septic shock after obtaining informed consents to treatment or control groups. Patients assigned
to the treatment group receive a 60-g loading dose of human albumin 20% over 2–3 h. Serum albumin levels are
maintained at least at 30 g/l in the ICU for a maximum of 28 days following randomization using 40–80 g human
albumin 20% infusion. The control group is treated according to the usual practice with crystalloids as the first
choice for the resuscitation and maintenance phase of septic shock. The primary endpoint is 90 days mortality and
secondary endpoints include 28-day, 60-day, ICU, and in-hospital mortality, organ dysfunction/failure, total amount
of fluid administration and total fluid balance in the ICU, and lengths of ICU and hospital stay. In total, 1412
patients need to be analysed, 706 per group. For the sample size estimation, a 15% reduction in 90-day mortality is
assumed, i.e. an absolute reduction of 7.5% points to 42.5% (relative risk 1.18). Assuming a dropout rate of 15%, a
total of 1662 patients need to be allocated.
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Discussion: The results of the clinical trial may influence the treatment of patients with septic shock. The expected
improvement in patient survival may result in a reduction in the resources currently used in the treatment of these
patients and in the socioeconomic burden of this disease.
Trial registration: ClinicalTrials.gov NCT03869385. Registration on 18 July 2019. Protocol version: Final 3.0.
Keywords: Septic shock, Fluid resuscitation, Albumin
Background
Sepsis is the 10th leading cause of death in the high-income
countries and is the leading cause of death in the intensive care
unit (ICU) [1]. It represents a significant burden on the health-
care system [2, 3]. Several sepsis-specific therapeutic approaches
have been evaluated for efficacy and effectiveness in recent de-
cades, but failed to produce the expected results [4–6].
In addition to its oncotic functions, albumin has a var-
iety of other properties, including binding and transport
of various endogenous molecules [7], anti-inflammatory
[8] and anti-oxidative effects [9], and modulation of ni-
tric oxide metabolism [10]. These properties are particu-
larly relevant in critically ill patients, especially in
patients with sepsis. In 1998, a Cochrane meta-analysis
reported increased mortality associated with albumin ad-
ministration in critically ill patients [11]. However, when
further clinical studies were included in another meta-
analysis by Wilkes et al., the safety of albumin therapy
was confirmed, but with no corresponding survival bene-
fit [12]. Interestingly, a later meta-analysis by Vincent
et al. showed that the use of human albumin in critically
ill patients could reduce morbidity [13]. Significant im-
provement in organ function of critically ill patients was
confirmed in a pilot study in which albumin therapy was
administered with the aim of maintaining serum albu-
min concentrations greater than 30 g/l [14].
Based on the contradictory literature cited earlier, a
large randomized, prospective, double-blind study was
performed in 7000 critically ill patients (SAFE study)
[15]. In this study, the possible effect of volume replace-
ment therapy with human albumin 4% on the outcome
of these patients was compared to volume replacement
therapy with only crystalloids. Although the survival
rates in the two groups were similar, a post hoc analysis
of 1218 patients with severe sepsis showed decreased
mortality in the albumin group compared to patients
treated with 0.9% saline solution alone [15]. Conse-
quently, the ALBumin Italian Outcome Sepsis (ALBIOS)
study investigated the possible impact on outcome of al-
bumin administration and maintenance of serum albu-
min concentrations to at least 30 g/l in 1810 patients
with severe sepsis and septic shock [16]. The study
showed no outcome difference between the study
groups. Nevertheless, there was a tendency for a poten-
tial survival benefit of albumin therapy in patients who
started therapy 6–24 h after onset of sepsis compared to
those who started it earlier. Moreover, in the 1121 pa-
tients with septic shock, 90-day mortality was lower in
the albumin group (564 patients) than in the non-
albumin group (43.6 vs. 49%, p = 0.03). Taken together,
the current evidence suggests that albumin administra-
tion in patients with severe and advanced sepsis who
have potential impairment of the protective effects of
serum albumin may provide a survival benefit. However,
no prospective, randomized trial has adequately studied
this hypothesis in patients with septic shock.
Aim of the study
The aim of the ARISS (Albumin Replacement in Septic
Shock) study is to investigate the effect of albumin ad-
ministration and maintenance of a serum albumin con-
centration of at least 30 g/l for 28 days in the ICU after
onset of septic shock compared to volume replacement
therapy without albumin on patient survival.
Methods/design
The ARISS study is a prospective, multicentre, random-
ized, controlled, parallel-grouped, open-label, interven-
tional clinical trial (phase IIIb) according to the German
Medicines Act (AMG). The information provided in this
manuscript corresponds to the most recent version of
the study protocol (Final 3.0 from 18 July 2019).
Hypothesis
We hypothesize that albumin administration started
within 6–24 h after the onset of septic shock aimed at
maintaining a serum albumin concentration of at least
30 g/l for 28 days after the onset of septic shock will re-
duce 90-day all-cause mortality in these patients com-
pared to volume replacement therapy without albumin.
Trial interventions
Patients admitted to the contributing ICUs during the
study period are assessed daily and are included in the
study if they develop septic shock during the ICU stay.
Eligible patients admitted to the contributing ICUs are
randomly assigned centrally by ZKS Jena (Centre for
Clinical Trials Jena) after obtaining informed consents to
treatment or control groups (Fig. 1). Intervention starts
within 6–24 h after the onset of septic shock. Patients
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assigned to the treatment group receive a 60 g loading
dose of human albumin (HA) 20% over 2–3 h, in
addition to the crystalloids required according to the
usual practice. Serum albumin levels are maintained at
least at 30 g/l in the ICU after randomization for a max-
imum of 28 days in the ICU using 40–80 g HA 20% infu-
sion. The following scheme is applied: serum albumin ≥
30 g/l, no administration; ≥ 25 g/l and < 30 g/l, 40 g over
1–2 h; ≥ 20 g/l and < 25 g/l, 60 g over 2–3 h; and < 20 g/l,
80 g over 3–4 h.
The control group is treated according to the usual
practice with crystalloids as the first choice for the resus-
citation and maintenance phase of septic shock. Patients
are followed up for 90 days after randomization for pri-
mary and secondary endpoints. An overview of the study
procedures is presented in Fig. 2.
Fig. 1 Flow chart representing the study interventions. SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment
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Concomitant medication/treatment
There are no restrictions to concomitant medication and
therapies during the trial. Treatment with human albu-
min in the control group is discouraged, unless deemed
to be necessary by the attending physicians. This should
be documented and justified.
Inclusion criteria
Patients who meet all the following inclusion criteria
may be included in this clinical trial:
1) Presence of septic shock that meets all the following
criteria [17]:
Clinically possible, probable, or
microbiologically confirmed infection according
to the definitions of the International-Sepsis-
Forums (ISF) [18]
Despite adequate volume therapy, vasopressors
are required to maintain mean arterial pressure
(MAP) ≥ 65 mmHg for at least 1 h
Serum lactate concentration > 2 mmol/l (18
mg/dl) despite adequate volume therapy
2) Onset of septic shock less than 24 h prior to study
inclusion, so that administration of the initial dose
of the trial product is possible within 6–24 h after
the onset of septic shock in the albumin group.
3) Age: ≥ 18 years
4) Written informed consent of the patient or his/her
legal representative (guardian) or confirmation of
the urgency of participation in the clinical trial and
the possible benefit to the patient by an
independent consultant or the implementation of
other established procedures to include patients
who are unable to provide informed consent.
5) Women of childbearing age: negative pregnancy
test
Exclusion criteria
Patients who meet any of the following exclusion criteria
are excluded from the trial: (1) moribund conditions
with life expectancy less than 28 days due to secondary
diseases or advanced malignant disease and palliative sit-
uations with life expectancy less than 6months; (2) “End
of life” decisions made before obtaining informed
Fig. 2 Schedule of the trial visits and study procedures. 1After obtaining informed consent. 2Basic data: sex, age, weight, height, time of hospital
admission, time of intensive care unit (ICU) admission, type of admission, referring facility prior to ICU admission, etc. from the 24-h period before
randomization (data from ICU or normal ward). 3Albumin group: determination of serum albumin concentration before administration of the
starting dose of the trial drug. 4Body temperature, respiratory rate, and haemodynamic parameters. 5Catecholamines, inotropic agents, diuretics,
volume replacement therapy, including blood transfusion, adjunctive sepsis therapy. 6Recording of concomitant medication with catecholamines
and inotropes at the corresponding time point (+/− 1 h); recording of concomitant medication with diuretics, volume therapeutics including
transfusion therapy, adjunctive sepsis therapy of the previous 6 h. 7Haemoglobin, creatinine, bilirubin, C-reactive protein, procalcitonin, leucocytes,
platelets, lactate, arterial blood gas analysis. 824-h time period prior to randomization. 9Procedures, mechanical ventilation, haemodynamic
monitoring. 10If adverse events (AEs) or serious adverse events (SAEs) are still “ongoing” after the end of treatment with the trial drug, observation
will continue until the end of data collection (day 90). 11Data on the vital status (alive/dead), if applicable date of death and cause of death,
residence after discharge, if applicable, recording of “End of Life” decisions
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consent; (3) previous participation in the study; (4) par-
ticipation in another interventional clinical trial within
the past 3 months; (5) Shock states that can be explained
by other reasons, e.g. cardiogenic, anaphylactic, and
neurogenic shock; (6) history of hypersensitivity to albu-
min or any other component of the trial product; (7) dis-
ease in which the use of albumin may be deleterious,
e.g., decompensated heart failure or traumatic brain in-
jury; (8) disease situations in which albumin administra-
tion may be advantageous, e.g. hepatorenal syndrome,
nephrosis, burns, and intestinal malabsorption syn-
drome; and (9) lactation.
Randomization
Randomization is carried out by an automated internet-
based service. The group assignment is retrieved via a
validated electronic tool (PaRANDies) by the respective
trial centre, based on a randomization list created in ad-
vance with nQuery Advisor 7.0. Randomization is strati-
fied according to serum lactate levels within 24 h before
inclusion in the trial: ≤ 8 mmol/l vs. > 8 mmol/l and ac-
cording to the trial centre.
Primary outcome measure
The primary endpoint is 90-day all-cause mortality.
Secondary outcome measures
Secondary end-points are (1) 28- and 60-day mortality;
(2) ICU and hospital mortality; (3) organ dysfunction/
failure as assessed by the Sequential Organ Failure As-
sessment (SOFA) Score: recorded daily up to 28 days in
the ICU after randomization in the study; (4) ICU and
hospital lengths of stay; (5) ventilator- and vasopressor-
free days, cost-benefit of volume replacement therapy;
(6) total amount of fluid administration and total fluid
balance; and (7) safety-related parameters: occurrence of
AEs and SAEs, especially anaphylactic shock, hypervo-
laemia, and pulmonary oedema.
Blinding
Albumin administration is adjusted after the starting
dose according to serum albumin concentrations. There-
fore, blinding is not possible.
Participant withdrawal
Participation in the clinical trial is voluntary. Each par-
ticipant has the right, at any time and without stating
reasons, to withdraw his/her consent prematurely from
the clinical trial without incurring disadvantages for his/
her further medical treatment. Withdrawal of consent
leads to termination of the clinical trial in the patient.
No further study-related measures is carried out, but the
stored data may continue to be used, as far as is neces-
sary to determine the effects of the intervention.
Suspension of protocol
Participation of a patient in the clinical trial may be pre-
maturely terminated for the following circumstances: (1)
death of the participant, (2) failure to obtain consent to
the continuation of the clinical trial, (3) refusal to con-
tinue the clinical trial by formerly incapacitated patients
who have regained their ability to consent, and (4) abort
at own request, withdrawal of consent to participate in
the clinical trial.
The principle investigator (PI) is entitled to interrupt
or terminate the clinical trial in a trial centre, possibly in
coordination with the Safety Committee and the biomet-
rician, if (1) the trial centre does not meet the technical
requirements specified in the study protocol; (2) the pro-
cedures related to the clinical trial do not comply with
the protocol; (3) there are serious, unexplained problems
with the quality of the collected data; (4) the recruitment
rate in the trial centre is inadequate; and (5) unpredict-
able circumstances have occurred in the respective trial
centre that does not allow the continuation of the clin-
ical trial. The PI is also entitled to interrupt or prema-
turely terminate the entire clinical trial for relevant
medical and administrative causes.
Adverse events (AEs)
Recording of AEs and sepsis-related adverse events be-
gins at randomization. Because human albumin is a nor-
mal constituent of human blood plasma, recording and
follow-up of AEs and SAEs for a maximum of 24 h after
the last dose of the trial drug is considered to be suffi-
cient. Therefore, AEs and sepsis-related adverse events
are recorded in the albumin group until 24 h after the
last dose of the trial drug and in the control group with-
out albumin until day 28 after randomization or until
discharge from the ICU, if it occurs before day 28 after
randomization. In the event that AEs or SAEs are still
“ongoing” after the above dates, they are tracked until
maximum the end of data collection (day 90). If they are
“ongoing” on day 90, they are documented as “not re-
covered”, “recovered with sequelae”, or “unknown”.
The intensity of adverse events is stratified to mild,
moderate, and severe (Table 1). Mild, moderate, and se-
vere adverse event can be serious or not. The following
points should be considered in defining AEs:
– An adverse event is defined as any adverse event that
occurs to a study subject that is not necessarily
causally related to the trial drug.
– Events plausibly explainable by sepsis are recorded
in both groups as sepsis-related clinical events in the
daily eCRF visits, but not as AEs (Table 1). Docu-
mentation of the sepsis-related clinical event as an
AE occurs only if the examiner suspects a connec-
tion with the administration of the trial drug.
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– The possible side effects of the trial drug may be
substance-specific and must be documented as AE
(Table 1).
– Clinically relevant worsening of a pre-existing dis-
ease not related to sepsis should be considered and
documented as an AE.
For each AE, whether an association with the trial
drug can be excluded or not is assessed. The type and
pattern of response, timing of administration, clinical
status of the patient, concomitant medication, and other
relevant clinical parameters are considered. Interruption,
discontinuation, or adjustment in the dosage of the trial
drug with regard to an AE are also documented. The
outcome of an adverse event is classified as follows: (1)
resolved, (2) resolved with sequelae, (3) not resolved, (4)
fatal, and (5) unknown.
A SUSAR is a suspected adverse effect that is both se-
vere and unexpected. An unexpected adverse effect is an
adverse effect that does not match the type and severity
of the known information about the trial drug. Occa-
sions for the reassessment of benefit and risk as well as
measures to protect against immediate danger are re-
ported within the specified deadlines.
Management of drug-related adverse events
The decision to discontinue or to continue treatment
with the trial drug from a medical point of view is at the
discretion of the treating physicians. Mild drug-related
reactions, such as flush, urticaria, fever, and nausea, usu-
ally disappear quickly when the infusion rate is reduced
or the infusion is stopped. If such reactions occur, ap-
propriate therapy should be initiated if clinically indi-
cated. This includes therapy with antihistamines and
symptomatic therapy. In these cases, the trial drug
should be subsequently administered over a longer
period of time, with close monitoring of the relevant
clinical parameters. A new clinical evaluation and, if ne-
cessary, a continuation of treatment with the trial drug
should take place on the following day. If the reaction
reoccurs, the trial preparation is permanently stopped. If
anaphylactic shock occurs, infusion of the trial drug
should be discontinued and adequate treatment should
be initiated according to current recommendations for
treating shock. Administration of the trial drug is per-
manently stopped. If hypervolaemia is suspected, the
trial drug should be administered over a longer period of
time (up to 2x the prescribed duration) under close ob-
servation of the appropriate haemodynamic parameters.
If the association between the trial drug and hypervolae-
mia is confirmed, an increase in the severity of hypervo-
laemia is observed, or if life-threatening consequences
such as pulmonary oedema occur, administration of the
trial drug for that day should be stopped. A new clinical
evaluation and, if necessary, a continuation of the trial
drug should take place on the following day.
Statistics
Sample size
The sample size estimation was performed using SAS
9.4 (SAS Institute Inc., Cary, NC, USA). The 90-day
mortality in the control arm is estimated to be about
50% [2, 3, 19]. For the sample size estimation, a 15% re-
duction in 90-day mortality is assumed, i.e. an absolute
reduction of 7.5% points to 42.5% (relative risk 1.18).
The sample size was estimated taking into account a
centre variability (probably about 50 centres) in mortal-
ity of patients in the control arm of the study between
40 and 60% and a risk reduction between 12 and 18%
(coincidentally uniform). A Mantel-Haenszel chi2 test at
a two-tailed significance level of 0.05 with a power of
Table 1 Sepsis-related clinical events, possible side effects of
the trial drug, and classification of severity of adverse events
(AEs)
Sepsis-related clinical events
Death caused by severe sepsis or septic shock
Cardiovascular event requiring the administration of vasoactive
substances
Respiratory event: e.g. decrease in PaO2/FiO2 ratio, hypoxia, ARDS,
acute pulmonary dysfunction, and mechanical ventilation
Hepatic event: e.g. Liver failure or liver dysfunction
Renal event: e.g. Kidney failure, renal insufficiency
Haematological event: e.g. coagulopathy, thrombocytopaenia,
thrombocytosis
Neurological event: e.g. delirium, confusion








Transmission of infection (in addition to sepsis, see corresponding
section of the valid information brochure).
Classification of AEs according to severity
Mild: a clinical symptom or sign that is well/easily tolerated and
usually requires no intervention.
Moderate: clinical symptom or sign sufficient to interfere with
normal/daily activity, intervention may be required.
Severe: a clinical symptom or sign that results in severe disability,
inability to work or inability to perform everyday activities or daily
activities/work not possible, treatment or intervention usually
required.
ARDS acute respiratory distress syndrome
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80% requires 1412 patients to be analysed, 706 per arm,
to demonstrate such an effect. Assuming a dropout rate
of 15%, 1662 patients need to be randomized.
Analysis populations
The intention-to-treat (ITT) population include all pa-
tients enrolled in the study and randomized with at least
one observation made after randomization. The primary
efficacy and safety analyses will be performed in the ITT
population. All variables collected will be analysed in the
ITT population. The per-protocol population include all
ITT patients who do not have major study plan deviations.
A protocol deviation is classified as “major” if it signifi-
cantly affects the main target parameter (90-day mortal-
ity). As a sensitivity analysis, the primary efficacy analysis
will be repeated in the PP population. If there are differ-
ences between the randomized and the actual treatment,
an additional sensitivity “as-treated” analysis will be per-
formed. Data from all patients not included in the ITT
analysis will be listed as needed (Listing-Only-Set).
Statistical analysis of data
All collected data will be analysed using descriptive
methods in the two treatment groups. The primary end-
point, “90-day mortality”, will be analysed using a gener-
alized mixed model with the random effects “centre”
and “patient in centre” and the fixed effects Simplified
Acute Physiology Score (SAPS) II, SOFA, and “baseline
serum albumin value”, as well as “treatment group” to
the significance level alpha = 0.05 two-sided. The pri-
mary analysis will be conducted in the ITT population.
All secondary endpoints, unless included in the primary
analysis model, will be exploratively compared using ap-
propriate parametric and nonparametric tests between
treatment groups.
Additional sensitivity analyses will be done in the PP
population. If more than 10% of mortality data at day 90
are missing, multiple imputation analysis will be per-
formed based on observed mortality rates, SOFA scores,
ICU stay, and hospital stay.
A health economic cost-benefit analysis of volume re-
placement therapy of the ICU stay will be carried out up
to a maximum of day 28. The direct costs of colloid,
crystalloid, and albumin administration will be recorded
and the length of stay. At the patient level, DEALE (de-
clining exponential approximation of life expectancy)
[20] will be applied to calculate patient-specific life ex-
pectancy based on mortality rates in the general popula-
tion and in the disease-specific population.
The primary endpoint and selected secondary end-
points (SOFA, organ failure defined as SOFA organ fail-
ure score ≥ 2) will be described for the following
subgroups: (1) baseline lactate ≤ 8 mmol/l versus > 8
mmol/l, and (2) SOFA total and subscores, SAPS II, and
APACHE II scores.
The final statistical report will be based on the specifi-
cations and checklist of the CONSORT statement on
the publication of randomized controlled trials in paral-
lel group design [21] and on regulatory requirements.
Interim analysis
Interim analysis is not planned.
Intervention accountability
The trial drug is supplied by the manufacturer to the
pharmacy of the Jena University Hospital. The pharmacy
of Jena University Hospital is responsible for the storage
as well as the transport of the trial drug to the trial cen-
tres or their local pharmacies. All deliveries to the con-
tributing centres are documented in the trial master file
(TMF) and the Investigator Site File (ISF). The respect-
ive ICU of the trial centre should be able to correctly
store the trial drug. Administration of the trial drug per
participant may only be carried out by the persons speci-
fied in the list of responsibilities and is documented in
writing in the ISF. Empty and opened bottles of the trial
drug per participant are collected and destroyed in the
trial centre.
Data registration
Data entry, processing, and evaluation carried out at
ZKS Jena comply with the provisions of the Data Protec-
tion Act. The data relevant for the clinical trial are col-
lected via RDE (Remote Data Entry) (Table 2). For this
purpose, the data are entered by the investigator or an
authorized member of the trial group on an online
workstation into special sheets, which represent an elec-
tronic CRF. The data are transferred directly to the trial
database in ZKS Jena via the electronic CRF. Name-
related identification of individual patients by the docu-
mentation centre is not required at any time during the
clinical trial. Transfer of patient-related medical data
from the trial centres to the documentation centre is
carried out using a pseudonym. No features are trans-
ferred that enable immediate identification of specific
patients by the documentation centre.
Data handling and record keeping
The data are recorded via a web application on the
servers of the ZKS of the Jena University Hospital using
the study management software “OpenClinica®”. Verifi-
cation of the accuracy of the data is done by computing
range, validity, and consistency checks. Implausible or
missing data are requested from the trial centre. Any
change to the data is documented via an automatic
change tracking (audit trail) in the database. As a docu-
mentation centre, ZKS Jena is also responsible for data
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Table 2 Data collection during the trial
Screening and 24-h period before randomization:
• Basic data (sex, age, weight, height, time of hospital admission, time of ICU admission, type of admission, referring facility prior to transfer to the
ICU), onset of septic shock, primary or secondary admission diagnoses, and concomitant diseases
• Data on infection, microbiology, anti-infective therapy, and raw data for the calculation of APACHE II, SAPS II, and SOFA scores
• Assessment of concomitant medication (catecholamines, inotropes, diuretics, fluid therapy including transfusion, adjunctive sepsis therapy)
• Intensive care interventions (intubation, central venous catheter, arterial catheter, renal replacement therapy, ventilation, extracorporeal
membrane oxygenation, haemodynamic monitoring)
• Clinical parameters (body temperature, respiratory frequency, haemodynamic parameters (systolic arterial pressure, mean arterial pressure,
diastolic arterial pressure, central venous pressure, cardiac output))
Time of randomization:
• Data on infection, microbiology, anti-infective therapy, clinical parameters, and concomitant medication
• Routine data from the laboratory, performed in the 24-h period before randomization: haemoglobin, creatinine, bilirubin, C-reactive protein, pro-
calcitonin, leucocytes, platelets, lactate, arterial blood gas analysis, and intensive care interventions
• AEs, SAEs, sepsis-related clinical events
Time period until 2 h after randomization:
• Data on infection, microbiology, and anti-infective therapy
• AEs, SAEs, and sepsis-related clinical events
• Data on trial drug administration
Trial visit at 6 h after randomization:
• Data on infection, microbiology, anti-infective therapy, and co-medication with catecholamines and inotropes
• Concomitant medication with diuretics, fluid therapy including transfusion, adjunctive sepsis therapy, and clinical parameters
• Routine laboratory data (haemoglobin, lactate, arterial blood gases) and intensive care interventions
• Capturing of AEs/SAEs, sepsis-related clinical events and recording vital status (alive/dead)
• Data about administration of the trial drug
Trial visits on trial days 1 to 28 after randomization:
• Blood sampling to determine the serum albumin concentration
• Data on infection, microbiology, anti-infective therapy, and raw data for calculation of the SOFA score on the respective study day; the “worst”
daily value should be recorded
• Concomitant medication, intensive care interventions, and the amount of enteral and parenteral fluid adminstration
• Routine laboratory data and clinical parameters, 24 h urinary output, other fluid loss
• AEs/SAEs, sepsis-related clinical events, and vital status (live/dead)
• Data on administration of the trial drug
Data are collected from participants at one of the following time points, whichever comes first: Discharge from the hospital before or on trial
day 28, discharge from the hospital up to and including trial day 90, trial day 90 reached in the hospital (regular end of study), early termination of
the clinical trial. These data include:
• Ongoing SAEs and serious sepsis-related clinical events
• Vital status (alive/dead): if applicable, date of death and cause of death; if applicable, recording of “end of life” decisions, stay after discharge
• ICU length of stay (of the first ICU stay after study participation)
• Hospital length of stay (first hospital stay after study participation)
• If the patient is discharged from the ICU or the hospital during the 90-day observation period, this time is defined as the endpoint for determin-
ing the ICU length of stay and/or hospital stay. If the patient returns to the ICU or hospital within the 90 days, this is no longer relevant for the col-
lection of trial endpoints.
Data collection at trial days 28, 60, and 90 after randomization:
• Vital status (alive/dead): if applicable, date of death and cause of death; if applicable, recording of “end of life” decisions, stay after discharge
• Verification of the documentation of SAEs already detected and serious sepsis-related clinical events, possibly AEs, which are “ongoing” at the re-
spective time point
APACHE Acute Physiology and Chronic Health Evaluation, AE adverse events, SAE serious adverse event, SAPS Simplified Acute Physiology Score, SOFA Sequential
Organ Failure Assessment
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storage. The main clinical trial documents, including the
data entry forms, will be kept for at least 30 years after
termination of the clinical trial. The medical records and
other original data must be kept for the longest possible
period of time allowed by the hospital, institution, or
private practice, but not less than 30 years.
Monitoring
Monitoring of the trial is performed by ZKS Jena. This
includes selection visits, initiation visits for training and
briefing of the trial group prior to the start of recruit-
ment or a central initiation, regular on-site visits as well
as concluding visits for the correct closure of the trial
centres. Monitoring is be carried out according to the
standard operating instructions of ZKS Jena. The investi-
gators provide the monitor direct access to the original
data and documents.
Within the scope of quality assurance, the IP can have
an independent audit conducted at any time in the par-
ticipating institutions. Inspections as part of the moni-
toring of ongoing or already completed clinical trials are
carried out by the competent authority.
Ethical considerations
The clinical trial is conducted in agreement with the
German Law on Marketing Authorisation for Medicinal
Products (AMG), the ordinance on the Application of
Good Clinical Practice in Conducting Clinical Trials
with Medicinal Products (GCP-V) [22], and the ethical
principles set out in the Helsinki Declaration in 2008 for
clinical trials as a recognized ethical basis [23].
Ethical approvals
The leading Ethics Committee (EC) is the EC respon-
sible for the Sponsor site (University of Jena, Bachstrasse
18, 07740 Jena, Germany) which has approved the
current version of the protocol (Reg.-Nr.: 2018-1227-
AMG_ff. Protokoll-Nr.: ZKSJ0122_ARISS). The ECs of
the respective centres should approve the study protocol
before recruitment of patients begins in each centre.
Informed consent
Eligible patients are informed of the study prior to initiat-
ing the study-related interventions. In addition, the trial
centres should adopt the locally established procedure for
including patients who are unable to consent and follow
the recommendations of the local ethics committee. The
presumed will of the patient should be considered.
Consent to participate in the clinical trial may be given
in writing by the guardian or legal representative of the
patients as soon as possible (Additional file 1). In any
case, if an eligible patient is unable to provide informed
consent and a legal representative is not yet assigned,
this must be established at the latest within 72 h. All
patients who regain their ability to consent for participa-
tion in the trial should provide their informed consent
to continue in the trial. Patients in the albumin group
may decide at this time or later not to continue adminis-
tration of the trial product (discontinuation of treat-
ment). The data collected until withdrawal from
participation in the trial are considered in the statistical
analysis.
Safety Monitoring Committee (SMC)
The data and safety monitoring board is an independent
committee composed of a group of individuals (three in-
dependent physicians/scientists, one of them a statisti-
cian) with relevant experience (Table 3). The main task
of the Committee is to monitor the safety and efficacy of
the use of the trial drug during the clinical trial. This
committee makes recommendations for the continu-
ation, modification, or termination of the clinical trial.
The SMC receives all safety-related data and informa-
tion every year to conduct an independent review of the
safety of the clinical trial. The results will be brought to
the attention of the competent authorities and the lead-
ing ethics committee as part of the annual safety report
or as necessary.
Audits and inspections
Within the scope of quality assurance, the PI can have
an independent audit conducted at any time in the par-
ticipating institutions. In this case, the investigator or
the participating institution grants the auditor access to
all documents necessary for the audit.
Inspections as part of the monitoring of ongoing or
already completed clinical trials are carried out by the
competent authority. The inspection conducted by the
competent authority will be carried out in accordance
with a written procedure and a pre-determined plan.
Insurance
Subject insurance is concluded for all patients included
in the study (HDI Gerling Industrie Versicherung AG,
30659 Hannover). The seat, policy number, telephone
number, and fax number of the insurance company is
included in the patient information form. Patients are
informed about their rights and obligations in connec-
tion with the insurance. Each participant in the clinical
trial receives the conditions of insurance in writing.
Duration
The maximum duration of treatment (administration of
the trial drug) in the albumin group is 28 days. Data col-
lection ends on study day 90 after randomization. The
planned recruitment period is approx. 36 months. The
trial ends on the day on which all data in the eCRF have
been recorded and monitored.
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Low recruitment contingency plan
In the case of low recruitment, more centres will be in-
cluded in the trial (up to 50 centres).
Timeline
 2018–2019: Protocol, approvals from the ethics
committees, trial tool development (eCRF and
randomization system)
 2019–2022: Inclusion of patients
 2023: The database is expected to be closed 90 days
after the inclusion of the last patient. This will be
followed by data analysis, writing of the manuscript,
and submission for publication.
Trial organization
The structure of the trial organization is presented in
(Table 3).
Table 3 Organizational structure of the clinical trial
Function/qualification Name Affiliation
Sponsor according to AMG Friedrich Schiller University Jena
Sponsor’s legal representative and principal
investigator (PI)
Prof. Dr. Yasser Sakr Universitätsklinikum Jena, Klinik für
Anästhesiologie und Intensivmedizin
Representative of the PI Prof. Dr. Michael Bauer Universitätsklinikum Jena, Klinik für
Anästhesiologie und Intensivmedizin
Co-PI Prof. Dr. Luciano Gattinoni
Prof. Dr. Michael Quintel
Universitäts klinikum Göttingen
Protocol committee Prof. Dr. Yasser Sakr,




Prof. Dr. Michael Hartmann,
PD Dr. Michael Kiehntopf
Prof. Dr. Luciano Gattinoni
Prof. Dr. Michael Quintel
Universitätsklinikum Jena, Klinik für
Anästhesiologie und Intensivmedizin




Study statistician Dr. Ulrike Schumacher Universitätsklinikum Jena, Zentrum für
Klinische Studien (ZKS)
Project management Dr. Sabine Barta
Dr. Christine Gampe
Barbara Schaarschmidt
Universitätsklinikum Jena, Zentrum für
Klinische Studien
Data management Aicko Helbig Universitätsklinikum Jena, Zentrum für
Klinische Studien
Monitoring Dr. Christine Gampe
Silvia Apel
Universitätsklinikum Jena, Zentrum für
Klinische Studien
Universitätsklinikum Göttingen, Zentrum für
Klinische Studien
Pharmacovigilance (safety management) Dr. Mariann Städtler
Sandra Birr
Universitätsklinikum Jena, Zentrum für
Klinische Studien
Central pharmacy for storage and dispatch of the
trial drug to trial centre pharmacies
Prof. Dr. Michael Hartmann Apotheke, Universitätsklinikum Jena
Pharmacies for the provision of the trial drug to
the trial centres
Local pharmacy of the respective trial centre
Pharmacoeconomic analysis Prof. Dr. Michael Hartmann Apotheke, Universitätsklinikum, Jena
Safety Monitoring Committee (SMC) Prof. Dr. Ricard Ferrer
Prof. Dr. Marco Ranieri
Dr. Hassane Njimi
Dept. of Intensive Care, Hospital Universitari
Vall d’Hebron Barcelona, Spain
Dept. of Anesthesiology and Intensive Care,
Sapienza University of Rome, Italy
Dept. of Critical Care, Erasme Hospital, Free
University of Brussels, Belgium
Responsible higher federal authority Paul-Ehrlich-Institut (PEI), Bundesinstitut für
Impfstoffe und biomedizinische Arzneimittel
Responsible state authority Thüringer Landesamt für Verbraucherschutz (TLV)
Leading ethics committee Ethik-Kommission der Friedrich-Schiller-Universität
Jena
Contributing centres SepNet - Critical Care Trials Group, Germany
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Publication plan
The aim is to publish the results of this clinical trial in
an international medical journal. Authorship is based on
the following criteria: (1) substantial contribution to the
conception or design of the manuscript or to the collec-
tion, analysis, and interpretation of data for the manu-
script; (2) substantial intellectual contribution to
manuscript preparation; (3) final assessment or approval
of the manuscript version to be published; and (4) dec-
laration of responsibility for all aspects of the work to
ensure that issues related to the accuracy or integrity of
part of the work are adequately investigated and an-
swered. Authors should meet all four criteria.
Subsequent changes in the trial protocol—amendments
Changes in the trial protocol requiring approval will be
applied for by the PI and will be implemented only if
they have been approved by the responsible federal au-
thority. This excludes amendments that are necessary in
order to avert immediate danger to the concerned per-
sons, which must be implemented immediately. A
favourable evaluation should be obtained from the re-
sponsible EC. To ensure largely comparable conditions
in all trial centres and in the interest of a flawless data
evaluation, there is no intention to perform any amend-
ment or changes to the trial conditions agreed upon in
the trial protocol.
Perspectives
The results of the clinical trial may influence the treat-
ment of patients with septic shock. The expected im-
provement in patient survival may result in a reduction
in the resources currently used in the treatment of these
patients and in the socioeconomic burden of this dis-
ease. If the hypothesis cannot be confirmed, restrictive
albumin administration will be justified and the costs of
therapy can be significantly reduced. In both cases, the
results of the clinical trial could reduce the socio-
economic burden of the disease and will be of high clin-
ical relevance.
Discussion
Therapeutic approaches in patients with septic shock are
controversial. The current evidence suggests that albu-
min administration may improve the outcome of such
patients. However, there are no prospective randomized
studies that have adequately investigated the possible
impact of albumin therapy on the outcome of patients
with septic shock. In the ARISS trial, patients are ran-
domized into two groups. The trial product is adminis-
tered only in the albumin group for a maximum of 28
days and only while in the ICU. Patients in the albumin
group receive the starting dose of the trial product for
the first time within 6–24 h after the onset of septic
shock, based on a subgroup analysis of the ALBIOS
study [16], which demonstrated a survival advantage in
the intervention group compared to the control group.
Patients receive a starting dose of 60 g of 20% human al-
bumin over 2–3 h within 6–24 h after the onset of septic
shock. Crystalloids are administered according to usual
practice in this condition. The prescribed dose of albu-
min has been used in previous clinical trials and is con-
sidered to be safe [14, 16]. In addition, these studies
showed a potential advantage of albumin administration
in terms of morbidity [14] and mortality [16].
Dose adjustment follows a predetermined schedule
with the aim of maintaining serum albumin concentra-
tion at least at 30 g/l. The serum albumin concentration
represents a valid treatment target for the trial drug. It is
routinely determined in critically ill patients receiving al-
bumin. The target value of at least 30 g/l corresponds to
the target value from previous studies that showed a po-
tential advantage of albumin administration in terms of
morbidity [14] and mortality [16] without any safety
concerns. Taken together, the study intervention is justi-
fied, low-risk, and clinically relevant.
It is expected that the exclusion criteria will not ex-
clude more than 10–20% of patients with septic shock
from participating in the clinical trial. Therefore, high
generalizability of the results is expected. The results of
the clinical trial are expected to impact on everyday clin-
ical practice and will have a direct impact on guidelines
for the treatment of patients with septic shock. If the
established hypothesis can be confirmed, then albumin
administration will improve the outcome of patients
with septic shock and justify the higher costs of such
therapy.
Trial status
The current protocol version is “Final 3.0.”, as for July 7,
2019. The first patient was randomized to the study on
21 October 2019. A total of 15 centres were able to re-
cruit patients to the study. As for July 1, a total of 94 pa-
tients were included in the study. Recruitment is
estimated to end in September 2023.
Supplementary Information




AE: Adverse event; AMG: Arzneimittelgesetz (medicinal products act); APAC
HE: Acute Physiology and Chronic Health Evaluation; CRF: Case report form;
DFG: Deutsche Forschungsgemeinschaft; EK: Ethics Committee; GCP: Good
Clinical Practice; ICU: Intensive care unit; ISF: Investigator Site File; PEI: Paul-
Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische
Arzneimittel; SAPS: Simplified Acute Physiology Score; SAE: Serious adverse
event; SMC: Safety Monitoring Committee; SOFA: Sequential Organ Failure
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Assessment; SUSAR: Suspected unexpected serious adverse reaction;
TMF: Trial Master File; ZKS: Zentrum für klinische Studien (Centre for Clinical
Studies)
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